PLK4 inhibitor RP-1664

{
  "id": "MLC-T-ONC-016120",
  "term": "PLK4 inhibitor RP-1664",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of polo-like kinase 4 (PLK4), with potential antineoplastic activity. Upon oral administration, PLK4 inhibitor RP-1664 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. This inhibits the proliferation of tumor cells that overexpress PLK4 and/or tripartite motif-containing protein 37 (TRIM37). PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle. Tumors with a high level of the E3 ubiquitin-protein ligase TRIM37 rely on PLK4 for survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/plk4-inhibitor-rp-1664/"
}